iOncologi is a Florida company using RNA in layered fat particles to train the immune system against solid tumours. Its first programme is in an early trial in glioblastoma.
iOncologi, Inc., a clinical-stage company in Gainesville, Florida, develops RNA immunotherapies under a patent exclusively licensed from the University of Florida Research Foundation. Its multilamellar RNA nanocomplex platform delivers RNA in layered lipid particles to prime a broad immune response; IONC102 pairs the platform with off-the-shelf antigens optimised with SandboxAQ and is in phase 1 in glioblastoma, according to the company. A 2026 National Cancer Institute STTR award funds iOi7, an autologous, ex vivo-expanded immunomodulatory haematopoietic stem cell therapy, for immune checkpoint inhibitor-resistant glioblastoma, including a move to closed, scalable manufacturing.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR (R42) award 4R42CA302331-02: Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
IONC102 is an experimental RNA immunotherapy from iOncologi that is being tested in an early trial in glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/